07:01 AM EST, 11/13/2026 (MT Newswires) -- The European Medicines Agency's Committee for Medicinal Products for Human Use recommended for approval Fortvita Biologics (Ireland)'s non-squamous non-small cell lung cancer drug Zybrivo. Zybrivo, or sintilimab, in combination with chemotherapy, improved first-line progression-free survival in adults with non-squamous non-small cell lung cancer, compared with chemotherapy alone, according to a Friday notice. The drug is subject to a final marketing authorization decision by the European Commission.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.